Skip to main content
Fig. 4 | Cancer Imaging

Fig. 4

From: Most-enhancing tumor volume by MRI radiomics predicts recurrence-free survival “early on” in neoadjuvant treatment of breast cancer

Fig. 4

Kaplan-Meier recurrence-free survival estimates for METV at the early treatment time point using the highest quartile cut-point (Q3) with corresponding p-values by hormone-receptor status subgroup: hormone-receptor positive and HER2 negative (N = 66, left), HER2 positive (N = 38, middle), and triple negative (N = 36, right) with corresponding p-values (for 2 cases the hormone receptor status was unknown)

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us